Table 7.
Key characteristics of the insulin glargine market (100 IU/ml) among European countries.
| Bio Usage (%) | Price difference at launch (Bio vs. Originator) % | Price difference originator over time (%) | Latest price difference (Bio vs. Originator—%) | % Gla-300 (latest) | |
|---|---|---|---|---|---|
| Albania | NA | NA | −32.2 | NA | 45.3 |
| Bosnia and Herezegovina | 6.2 | 0.0 | −11.3 | −7.9 | 52.1 |
| Bulgaria | 11.0 | −4.7 | −10.8 | −5.7 | |
| Catalonia | 12.4 | −23.1 | −23.1 | Similar | 28.1 |
| Estonia | 0.69 | −16.4 | −24.9 | 55.4 | |
| Hungary | 24.6 | −28.2 | −21.1 | −1.6 | 58.0 |
| Italy | 25.0 | −52.3 | −24.0 | 30.4 | |
| Latvia | NA | NA | −14.4 | NA | 51.4 |
| Lithuania | 26.5 | −12.3 | −21.1 | 0.0 | 39.0 |
| Poland | 44.8 | −24.6 | −31.1 | −0.2 | 37.1 |
| Scotland | 19.5 | −18.1 | −9.0 | −7.5 | 9.3 |
| Slovenia | 15.7 | −22.9 | −20.3 | −9.9 |
NB: Bio usage, % insulin glargine biosimilar vs. total insulin glargine 100 IU/ml on a DDD basis; Orig, Originator; Gla-300, TOUJEO 300 IU/ml on a DDD basis; Blanks represent no data available; NA, Biosimilars not yet launched; Latest price difference either 2019 or 2020 depending on available data; price differences calculated on a DDD basis using local currencies.